Evidence map›Paper›PMID 34022708›Full record

ArticleBioorganic chemistry2021

Discovery of anti-infective adipostatins through bioactivity-guided isolation and heterologous expression of a type III polyketide synthase.

Lukuan Hou, Ying Li, Qihao Wu, Miyang Li, Ethan A Older, Xiaoyu Tang, Prakash Nagarkatti, Mitzi Nagarkatti, Yuan Liu, Lingjun Li and 4 more

Abstract read
In one paragraph

Article in Bioorganic chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Identification and distribution of a downregulatory signaling alkyloxazole inProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lukuan HouDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, United States.
Ying LiDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, United States; College of Pharmacy, Southwest Minzu University, Chengdu 610041, China.
Qihao WuSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, United States.
Miyang LiDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI 53705, United States.
Ethan A OlderDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, United States.
Xiaoyu TangInstitute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Prakash NagarkattiDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC 29209, United States.
Mitzi NagarkattiDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC 29209, United States.
Yuan LiuSichuan Provincial Qiang-Yi Medicinal Resources Protection and Utilization Technology and Engineering Laboratory, and Ethnic Medicine Institute, Southwest Minzu University, Chengdu 610041, China.
Lingjun LiSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, United States.
Daping FanDepartment of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC 29209, United States.
Tim S BugniSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, United States.
Zhuo ShangDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, United States. Electronic address: SHANGZ@mailbox.sc.edu.
Jie LiDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, United States. Electronic address: LI439@mailbox.sc.edu.

Funding

Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
Mass Spectrometric Studies of Neuropeptides in FeedingR01DK071801 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2006 to 2026
$6.7M
Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
NCRR NIH HHS S10 RR029531NIDDK NIH HHS R01 DK071801NIGMS NIH HHS P20 GM103641
6 · The paper itself

Abstract

Antibiotic resistance and emerging viral pandemics have posed an urgent need for new anti-infective drugs. By screening our microbial extract library against the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the notorious ESKAPE pathogens, an active fraction was identified and purified, leading to an initial isolation of adipostatins A (1) and B (2). In order to diversify the chemical structures of adipostatins toward enhanced biological activities, a type III polyketide synthase was identified from the native producer, Streptomyces davawensis DSM101723, and was subsequently expressed in an E. coli host, resulting in the isolation of nine additional adipostatins 3-11, including two new analogs (9 and 11). The structures of 1-11 were established by HRMS, NMR, and chemical derivatization, including using a microgram-scale meta-chloroperoxybenzoic acid epoxidation-MS/MS analysis to unambiguously determine the double bond position in the alkyl chain. The present study discovered SARS-CoV-2 main protease inhibitory activity for the class of adipostatins for the first time. Several of the adipostatins isolated also exhibited antimicrobial activity against selected ESKAPE pathogens.

Indexed as

AcyltransferasesAnti-Infective AgentsBacterial ProteinsCoronavirus 3C ProteasesCOVID-19Drug Evaluation, PreclinicalGram-Negative BacteriaGram-Positive BacteriaHumansInhibitory Concentration 50Magnetic Resonance SpectroscopyMicrobial Sensitivity TestsMolecular ConformationPhylogenyRecombinant ProteinsResorcinols3C-like proteinase, SARS-CoV-2AcyltransferasesAnti-Infective AgentsBacterial ProteinsCoronavirus 3C Proteasesflavanone synthetaseRecombinant ProteinsResorcinolsESKAPE pathogens inhibitionHeterologous expressionNew adipostatinsSARS-CoV-2 main protease inhibitionType III polyketide synthase

Identifiers

PMID34022708
PMCPMC9013261

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.